Thread by @Vims9886

#betadrugs

AR FY21-22

MY TWO CENT .

If you like please RT

Second wave of COVID 19 impacted lives ,bussiness across the board.

We have also started to see inflation across economic in the world, interest rate increase & with ukrarian war conflict,supply chain constraints.

2/n
Even the world experienced chaos and disruption, we delivered our highest growth .

FY22 revenues grew by 58% to 183.84 crores while consolidated EBITDA grew by 72% to Rs 43.5 crore from 25.24 compared with the year ago period. EBITDA margins expanded to 23.6 % from 21.7%

3/n
Net profit too increased by 112% to Rs 24.8crores from Rs 11.7 crores compared with the same period a year ago.
#betadrugs commands a strong position in the Indian market with more than 112 SKUs and its products are available across all major Corporate & Govt hospitals.

4/n
#betadrugs continues to onboard new hospitals every month and is focused on expanding its branded product portfolio in the existing hospitals too. The company aims to become one of the top ten branded generic players in the oncology market in the near future.

5/n
#betadrug is poised for strong growth for the next few years on the back of its strong R&D efforts to develop complex generics in the oncology space and cont expansion into new geographies.Beta is focused on getting plant approvals and has many audits lined up for this year.

6/n
is cont. to file new product registrations across ROW countries & poised to enter regulated mkt soon.
Beta had strong pipeline of 23 prodcts which are going off-patent in nxt 5 yr includes NIBs,NDDS & PARP (chemo)inhibitors which will support top line & margin expansion

7/n
#beta is also expanding its API capabilities by developing new products.It plans to file CEP by Oct 22.This backward integration helps to cont. expand margins.#beta has further got an allotment of 12 acres of land on 95yr lease in special area allocated for API

8/n
This will help company to take care of its future API capacity expansion.
company is consolidating its institutional business & is cont. adding new logos every year.Beta has also entered into longterm partnership with three MNC pharma companies for its CMO business

9/n
We believe that all our segments are slated to clock healthy growth with EBITDA margins in the range of 24% to 25%.
On behalf of the Board and management, I would like to thank our shareholders, customers

10/n
Subsidiary
#Beta UBK international ( Uzbekistan) 60 % shareholding
2.adley formulation 100% shareholding.
3. Adley lab 100% shareholding

11/n
Performance
Beta Uzbekistan
Engaged primarily in mfg oncology product approval were obtained on the last quarter ,
FY22 SALES couldn't happen in 21-22 ( probably turn around story)

12/n
Adley formulation is primarily engaged in manufacturing & trading of oncology product turnover rs 5115 laks with profit rs 501 lakhs

Adley lab in mfg in oncology API ( very few companies had own api) turnover rs 3400 lakh with profitability rs 555.45 lakh

13/n
30% salary hike ( imo negative)

Csr activities is done

Cashflows from operating activity almost double YOY ,( VERY GOOD SIGN) galle me bhi paisa a raha hai.

14/n
29 sept there is AGM also
Disc :
Top 5 holding
Not sebi register
May be biased🙏